Specific PPAR gamma agonists may have different effects on cancer incidence

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 854-

  Bambury, R M ^a   Iyer, G ^a   Rosenberg, J E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE;

ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CARCINOGENESIS; DIABETES MELLITUS; DIABETIC PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

EID: 84874571697     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt003     Document Type: Letter

References (3)

1. Kao CH, Sun LM, Chen PC et al. A population-based cohort study in Taiwan-use of insulin sensitizers can decrease cancer risk in diabetic patients? Ann Oncol 2013; 24: 523-530.
2. Elrod HA, Sun SY. PPARgamma and apoptosis in cancer. PPAR Res 2008; 2008:704165.
3. Colmers IN, Bowker SL, Majumdar SR et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184: E675-E683.